Thalidomide Therapy for VEOIBD
NCT06382519 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2025-05-22
Summary
This is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease
Conditions
- Inflammatory Bowel Diseases
Interventions
- DRUG
-
Thalidomide
thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.
Sponsors & Collaborators
-
Children's Hospital of Fudan University
lead OTHER
Principal Investigators
-
Ying Huang · Children's Hospital of Fudan University
Eligibility
- Min Age
- 28 Days
- Max Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-15
- Primary Completion
- 2025-12-31
- Completion
- 2026-12-31
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
NCT03234907 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
NCT03329209 ·Status: COMPLETED ·Phase: PHASE1
-
Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
NCT03221166 ·Status: TERMINATED ·Phase: PHASE3
-
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
NCT05321758 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Fecal Microbiota Transplantation in Pediatric Crohn's Disease
NCT05321745 ·Status: RECRUITING ·Phase: NA
-
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
NCT06315179 ·Status: RECRUITING
-
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT03138655 ·Status: COMPLETED ·Phase: PHASE2
-
The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness
NCT02423512 ·Status: COMPLETED
-
Therapeutic Endpoint in Pediatric IBD Conditions
NCT06065228 ·Status: RECRUITING
-
Synergistic Effect of Vedolizumab and Pentoxifylline
NCT02953275 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
NCT05481619 ·Status: RECRUITING ·Phase: PHASE4
-
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
NCT02038920 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Faecal Volatile Organic Compounds in the Diagnosis of Paediatric Inflammatory Bowel Disease
NCT03170622 ·Status: COMPLETED
-
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease
NCT01632462 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
NCT02039505 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis
NCT03235752 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
NCT04312659 ·Status: COMPLETED
-
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
NCT00606346 ·Status: ACTIVE_NOT_RECRUITING
-
A Multicenter Clinical Trial: Efficacy, Safety of Fecal Microbiota Transplantation for Inflammatory Bowel Disease
NCT04521205 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)
NCT05596422 ·Status: COMPLETED
-
Tacrolimus Versus Methotrexate as Rescue Therapy for Refractory Inflammatory Bowel Disease
NCT03204136 ·Status: UNKNOWN
-
Fecal Microbial Transplantation and Vedolizumab Treatment of Crohn's Disease
NCT04328922 ·Status: UNKNOWN ·Phase: NA
-
Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy
NCT03802214 ·Status: TERMINATED
-
Combined Immunosuppression for Pediatric Crohn's Disease
NCT05043870 ·Status: RECRUITING ·Phase: PHASE4